Detalles de la búsqueda
1.
A phase 2 trial exploring the significance of homologous recombination status in patients with platinum sensitive or platinum resistant relapsed ovarian cancer receiving combination cediranib and olaparib.
Gynecol Oncol
; 187: 105-112, 2024 May 16.
Artículo
en Inglés
| MEDLINE | ID: mdl-38759516
2.
Early drug development in solid tumours: analysis of National Cancer Institute-sponsored phase 1 trials.
Lancet
; 400(10351): 512-521, 2022 08 13.
Artículo
en Inglés
| MEDLINE | ID: mdl-35964611
3.
A phase 1 study of veliparib (ABT-888) plus weekly carboplatin and paclitaxel in advanced solid malignancies, with an expansion cohort in triple negative breast cancer (TNBC) (ETCTN 8620).
Breast Cancer Res Treat
; 198(3): 487-498, 2023 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-36853577
4.
Phase 2 study of ibrutinib in classic and variant hairy cell leukemia.
Blood
; 137(25): 3473-3483, 2021 06 24.
Artículo
en Inglés
| MEDLINE | ID: mdl-33754642
5.
Combined PARP and HSP90 inhibition: preclinical and Phase 1 evaluation in patients with advanced solid tumours.
Br J Cancer
; 126(7): 1027-1036, 2022 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-34887522
6.
Effect of removing race from glomerular filtration rate-estimating equations on anticancer drug dosing and eligibility: a retrospective analysis of National Cancer Institute phase 1 clinical trial participants.
Lancet Oncol
; 22(9): 1333-1340, 2021 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-34399096
7.
Outcomes of Pregnancy During Immunotherapy Treatment for Cancer: Analysis of Clinical Trials Sponsored by the National Cancer Institute.
Oncologist
; 26(10): e1883-e1886, 2021 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-34397143
8.
Clinical Activity and Safety of Cediranib and Olaparib Combination in Patients with Metastatic Pancreatic Ductal Adenocarcinoma without BRCA Mutation.
Oncologist
; 26(7): e1104-e1109, 2021 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-33742489
9.
Evaluation of toxicities related to novel therapy in clinical trials for women with gynecologic cancer.
Cancer
; 126(10): 2139-2145, 2020 05 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-32097505
10.
Phase II, Multicenter, Randomized Trial of Docetaxel plus Prednisone with or Without Cediranib in Men with Chemotherapy-Naive Metastatic Castrate-Resistant Prostate Cancer.
Oncologist
; 24(9): 1149-e807, 2019 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-31152080
11.
Beyond the dose-limiting toxicity period: Dermatologic adverse events of patients on phase 1 trials of the Cancer Therapeutics Evaluation Program.
Cancer
; 122(8): 1228-37, 2016 Apr 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-26916138
12.
Improved tumor oxygenation and survival in glioblastoma patients who show increased blood perfusion after cediranib and chemoradiation.
Proc Natl Acad Sci U S A
; 110(47): 19059-64, 2013 Nov 19.
Artículo
en Inglés
| MEDLINE | ID: mdl-24190997
13.
A phase II study of single-agent RO4929097, a gamma-secretase inhibitor of Notch signaling, in patients with recurrent platinum-resistant epithelial ovarian cancer: A study of the Princess Margaret, Chicago and California phase II consortia.
Gynecol Oncol
; 137(2): 216-22, 2015 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-25769658
14.
Combination cediranib and olaparib versus olaparib alone for women with recurrent platinum-sensitive ovarian cancer: a randomised phase 2 study.
Lancet Oncol
; 15(11): 1207-14, 2014 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-25218906
15.
A phase I study of the oral gamma secretase inhibitor R04929097 in combination with gemcitabine in patients with advanced solid tumors (PHL-078/CTEP 8575).
Invest New Drugs
; 32(2): 243-9, 2014 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-23645447
16.
A randomized phase II study of cediranib alone versus cediranib in combination with dasatinib in docetaxel resistant, castration resistant prostate cancer patients.
Invest New Drugs
; 32(5): 1005-16, 2014 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-24788563
17.
A phase II trial of sequential ribonucleotide reductase inhibition in aggressive myeloproliferative neoplasms.
Haematologica
; 99(4): 672-8, 2014 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-24362550
18.
Impact of the 2021 CKD-EPI equation on anticancer pharmacotherapy in black and non-black cancer patients.
Cancer Lett
; 586: 216679, 2024 Apr 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-38307411
19.
Circulating Tumor DNA Dynamics Fail to Predict Efficacy of Poly(ADP-ribose) Polymerase/VEGFR Inhibition in Patients With Heavily Pretreated Advanced Solid Tumors.
JCO Precis Oncol
; 8: e2300289, 2024 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-38412387
20.
Phase II Study of Erdafitinib in Patients With Tumors With Fibroblast Growth Factor Receptor Mutations or Fusions: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol K2.
JCO Precis Oncol
; 8: e2300407, 2024 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-38603650